Phase 3 Milestones Accelerate: Social media discussions praise Viking Therapeutics' rapid enrollment in the VANQUISH-1 Phase 3 trial for its obesity candidate VK2735, completed ahead of schedule. Enthusiasm builds around the dual agonist's subcutaneous and oral formulations advancing toward pivotal data. Investors highlight the program's potential to capture share in the exploding obesity market.
Fortress Balance Sheet Endures Burn: Chatter underscores the company's $706 million cash reserves, sufficient to fund multiple trials without near-term dilution. Despite a sharp rise in R&D spending, guidance points to moderated quarterly outflows. This financial runway supports upcoming maintenance dosing studies and novel amylin agonist development.
Buyout Buzz Intensifies: Voices on social media position Viking as an attractive acquisition for pharma giants eyeing obesity innovation. Analysts cited project price targets near $118, reflecting pipeline depth. Overall sentiment skews bullish amid competitive dynamics from established players.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) has made 0 purchases and 4 sales selling 233,409 shares for an estimated $7,692,120.
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 4 sales selling 57,661 shares for an estimated $1,901,405.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 4 sales selling 57,661 shares for an estimated $1,896,969.
- MATTHEW W FOEHR sold 16,000 shares for an estimated $561,694
- NEIL WILLIAM AUBUCHON (Chief Commercial Officer) purchased 4,475 shares for an estimated $149,912
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Viking Therapeutics Hedge Fund Activity
We have seen 203 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 2,030,259 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $71,424,511
- NORGES BANK removed 1,767,777 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,190,394
- D. E. SHAW & CO., INC. added 1,557,136 shares (+965.0%) to their portfolio in Q4 2025, for an estimated $54,780,044
- BLACKROCK, INC. added 1,015,708 shares (+18.2%) to their portfolio in Q4 2025, for an estimated $35,732,607
- BNP PARIBAS FINANCIAL MARKETS added 836,386 shares (+535.1%) to their portfolio in Q4 2025, for an estimated $29,424,059
- FMR LLC added 767,715 shares (+13.3%) to their portfolio in Q4 2025, for an estimated $27,008,213
- BRAIDWELL LP removed 759,455 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,717,626
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 3 analysts offer price targets for $VKTX in the last 6 months, with a median target of $102.0.
Here are some recent targets:
- Steve Seedhouse from Cantor Fitzgerald set a target price of $100.0 on 04/30/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 03/23/2026
- Edward Nash from Canaccord Genuity set a target price of $107.0 on 11/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
